Payment overview · 2025
General Payments
$715.78
58 reported records · 6 companies
Healthcare provider profile · identity verified
Ravi Kumar Titha, MD
Allopathic & Osteopathic Physicians|Internal Medicine · RICHLANDS, VA · NPI 1558452482
Verified facts
What the public records show
CMS Open Payments records show Ravi Kumar Titha, MD received $715.78 in general payments during 2025 across 58 reported records.
ABBVIE INC. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 277 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $290.21 | 40.5% | 25 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $208.33 | 29.1% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $151.91 | 21.2% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.00 | 3.4% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $23.11 | 3.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.22 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $715.78 | 58 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $290.21 | 25 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $208.33 | 22 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $85.39 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.10 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.42 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 277 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 90 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
277 | 68 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 1349 | 163 |
| Omeprazole | Omeprazole | 644 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 514 | 88 |
| Lisinopril | Lisinopril | 498 | 88 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 495 | 138 |
| Simvastatin | Simvastatin | 481 | 94 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 447 | 57 |
| Losartan Potassium | Losartan Potassium | 400 | 70 |
| Furosemide | Furosemide | 382 | 70 |
| Zolpidem Tartrate | Zolpidem Tartrate | 333 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 326 | 64 |
| Ibuprofen | Ibuprofen | 298 | 63 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 277 | 68 |
| Montelukast Sodium | Montelukast Sodium | 262 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 48 |
| Potassium Chloride | Potassium Chloride | 261 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 259 | 45 |
| Celecoxib | Celecoxib | 239 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 42 |
| Trazodone Hcl | Trazodone Hcl | 227 | 33 |
| Pregabalin | Pregabalin | 217 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 28 |
| Clonazepam | Clonazepam | 192 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 192 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 190 | 36 |
| Glimepiride | Glimepiride | 186 | 41 |
| Bupropion Xl | Bupropion Hcl | 167 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 164 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 153 | 33 |
| Levofloxacin | Levofloxacin | 153 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 27 |
| Atenolol | Atenolol | 142 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 26 |
| Metformin Hcl | Metformin Hcl | 132 | 30 |
| Meloxicam | Meloxicam | 131 | 24 |
| Buspirone Hcl | Buspirone Hcl | 130 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 22 |
| Baclofen | Baclofen | 125 | 26 |
| Clonidine Hcl | Clonidine Hcl | 122 | 22 |
| Allopurinol | Allopurinol | 117 | 21 |
| Azithromycin | Azithromycin | 115 | 72 |
| Prednisone | Prednisone | 115 | 38 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 113 | 28 |
| Naproxen | Naproxen | 108 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 103 | 15 |
| Sertraline Hcl | Sertraline Hcl | 101 | 19 |
| Cefuroxime | Cefuroxime Axetil | 98 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 17 |
| Estradiol | Estradiol | 92 | 18 |
| Carvedilol | Carvedilol | 91 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 17 |
| Ozempic | Semaglutide | 91 | 16 |
| Vraylar | Cariprazine Hcl | 90 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 87 | 32 |
| Symbicort | Budesonide/Formoterol Fumarate | 86 | 21 |
| Ondansetron Odt | Ondansetron | 84 | 25 |
| Ibu | Ibuprofen | 82 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 81 | 11 |
| Alprazolam | Alprazolam | 80 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 79 | 19 |
| Donepezil Hcl | Donepezil Hcl | 79 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 77 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 19 |
| Januvia | Sitagliptin Phosphate | 75 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 74 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 13 |
| Gemfibrozil | Gemfibrozil | 72 | 21 |
| Tramadol Hcl | Tramadol Hcl | 68 | 17 |
| Amoxicillin | Amoxicillin | 63 | 34 |
| Farxiga | Dapagliflozin Propanediol | 61 | 13 |
| Synthroid | Levothyroxine Sodium | 61 | suppressed |
| Linzess | Linaclotide | 59 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 59 | 13 |
| Doxepin Hcl | Doxepin Hcl | 55 | 15 |
| Glipizide | Glipizide | 53 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 53 | 12 |
| Mirtazapine | Mirtazapine | 53 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 53 | 25 |
| Nitroglycerin | Nitroglycerin | 51 | 15 |
| Lorazepam | Lorazepam | 50 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Sucralfate | Sucralfate | 45 | 12 |
| Eliquis | Apixaban | 44 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 44 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 11 |
| Clindamycin Hcl | Clindamycin Hcl | 43 | 29 |
| Promethazine Hcl | Promethazine Hcl | 43 | 14 |
| Alendronate Sodium | Alendronate Sodium | 40 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Famotidine | Famotidine | 40 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 11 |
| Fluconazole | Fluconazole | 39 | 19 |
| Methocarbamol | Methocarbamol | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Klor-Con M20 | Potassium Chloride | 35 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | suppressed |
| Ofloxacin | Ofloxacin | 34 | 20 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Premarin | Estrogens, Conjugated | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Klor-Con M15 | Potassium Chloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $715.78 · 58 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, FARXIGA, REXULTI, TRELEGY ELLIPTA, Topical Oxygen Chamber for extremities, VRAYLAR | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error